XTL Biopharma Settles Social Proxy Acquisition Claims
Ticker: XTLB · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: settlement, acquisition, legal
TL;DR
XTL Bio settles claims from Social Proxy acquisition, cleaning up past deals.
AI Summary
On November 11, 2024, XTL Biopharmaceuticals Ltd. entered into a settlement agreement with the CEO and previous shareholders of The Social Proxy Ltd., which XTL acquired. This agreement resolves outstanding claims related to the acquisition.
Why It Matters
This settlement resolves potential legal disputes arising from XTL's acquisition of Social Proxy, providing clarity on the financial and legal standing of the transaction.
Risk Assessment
Risk Level: low — The filing reports on a settlement agreement, which typically aims to reduce risk by resolving disputes.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Registrant
- The Social Proxy Ltd. (company) — Acquired subsidiary
- November 11, 2024 (date) — Date of settlement agreement
FAQ
What is the nature of the settlement agreement?
The settlement agreement is between XTL Biopharmaceuticals Ltd. and the chief executive officer and previous shareholders of The Social Proxy Ltd. to resolve outstanding claims related to the acquisition of Social Proxy by XTL.
When was the settlement agreement entered into?
The settlement agreement was entered into on November 11, 2024.
What is the relationship between XTL Biopharmaceuticals Ltd. and The Social Proxy Ltd.?
The Social Proxy Ltd. became a wholly owned subsidiary of XTL Biopharmaceuticals Ltd. pursuant to its acquisition.
What form does XTL Biopharmaceuticals Ltd. file annual reports under?
XTL Biopharmaceuticals Ltd. files annual reports under Form 20-F.
What is the primary business of XTL Biopharmaceuticals Ltd. according to the filing?
XTL Biopharmaceuticals Ltd. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 941 words · 4 min read · ~3 pages · Grade level 16.3 · Accepted 2024-11-12 09:15:17
Filing Documents
- ea0220818-6k_xtlbio.htm (6-K) — 17KB
- 0001213900-24-096334.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 12, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 3